1. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2018 (updated). 2020;31:119. Available from: http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm#1.
2. California Department of Public Health Office of AIDS. California HIV surveillance report 2019. 2019. Available from: https://www.cdph.ca.gov/Programs/CID/DOA/CDPH%20Document%20Library/California_HIV_Surveillance_Report2019_ADA.pdf.
3. Centers for Disease Control and Prevention. How effective is PrEP? 2021. Available from: https://www.cdc.gov/hiv/basics/prep/prep-effectiveness.html.
4. Centers for Disease Control and Prevention. PrEP for HIV prevention in the U.S. 2021. Available from: https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/PrEP-for-hiv-prevention-in-the-US-factsheet.html.
5. Gilead Sciences Inc. U.S. Food and Drug Administration approves expanded indication for Truvada® (emtricitabine and tenofovir disoproxil fumarate) for reducing the risk of acquiring HIV-1 in adolescents. Business Wire. 2018. Available from: https://www.businesswire.com/news/home/20180515006187/en/.